news
12-11-2016, 10:51 PM
Tensions inherent to drug pricing pit affordability against the need to recoup investment in research, raising questions about how much of the cost patients should have to bear.
More... (http://www.nytimes.com/2016/12/11/us/retro-report-medical-patents-profits.html?partner=rss&emc=rss)
More... (http://www.nytimes.com/2016/12/11/us/retro-report-medical-patents-profits.html?partner=rss&emc=rss)